Evidence map›Paper›PMID 34771129›Full record

ArticleMolecules (Basel, Switzerland)2021

Development of Triazoles and Triazolium Salts Based on AZT and Their Anti-Viral Activity against HIV-1.

Daniel Machado de Alencar, Juliana Gonçalves, Andreia Vieira, Sofia A Cerqueira, Cruz Sebastião, Maria Inês P S Leitão, Giulia Francescato, Paola Antenori, Helena Soares, Ana Petronilho

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Current medicinal chemistry · 2026
    Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Daniel Machado de AlencarITQB-NOVA-Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avd da Republica, 2780-157 Oeiras, Portugal.
Juliana GonçalvesHuman Immunobiology and Pathogenesis Laboratory, Chronic Diseases Research Center, NOVA Medical School, NOVA University of Lisbon, 1150-082 Lisbon, Portugal.ORCID 0000-0002-1237-4152
Andreia VieiraITQB-NOVA-Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avd da Republica, 2780-157 Oeiras, Portugal.ORCID 0000-0003-2138-8756
Sofia A CerqueiraHuman Immunobiology and Pathogenesis Laboratory, Chronic Diseases Research Center, NOVA Medical School, NOVA University of Lisbon, 1150-082 Lisbon, Portugal.
Cruz SebastiãoHuman Immunobiology and Pathogenesis Laboratory, Chronic Diseases Research Center, NOVA Medical School, NOVA University of Lisbon, 1150-082 Lisbon, Portugal.ORCID 0000-0003-1232-0119
Maria Inês P S LeitãoITQB-NOVA-Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avd da Republica, 2780-157 Oeiras, Portugal.ORCID 0000-0002-2201-6818
Giulia FrancescatoITQB-NOVA-Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avd da Republica, 2780-157 Oeiras, Portugal.ORCID 0000-0002-9199-130X
Paola AntenoriITQB-NOVA-Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avd da Republica, 2780-157 Oeiras, Portugal.
Helena SoaresHuman Immunobiology and Pathogenesis Laboratory, Chronic Diseases Research Center, NOVA Medical School, NOVA University of Lisbon, 1150-082 Lisbon, Portugal.
Ana PetronilhoITQB-NOVA-Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Avd da Republica, 2780-157 Oeiras, Portugal.
Universidade Nova de Lisboa · PTUniversity of Lisbon · PT

Funding

European Society of Clinical Microbiology and Infectious Diseases n/aFundação para a Ciência e Tecnologia CEECIND/01049/2020Fundação para a Ciência e Tecnologia CEECINST/001202/2018Fundação para a Ciência e Tecnologia IF/00109/2014/CP1244/CT0007Fundação para a Ciência e Tecnologia IF/01722/2013Fundação para a Ciência e Tecnologia PD/BD/128343/2017Fundação para a Ciência e Tecnologia PD/BD/135483/2018Fundação para a Ciência e Tecnologia SFRH/BD/135296/2017Fundação para a Ciência e Tecnologia SFRH/BD/1444412019Fundação para a Ciência e Tecnologia SFRH/BPD/124739/2016Fundação para a Ciência e Tecnologia UIDB/04612/2020Fundação para a Ciência e Tecnologia UIDP/04612/2020Gilead Génese PGG 009/2017Universidade Nova de Lisboa NOVASAUDE 2017
6 · The paper itself

Abstract

We report herein a set of 3'-azido-3'-deoxythymidine (AZT) derivatives based on triazoles and triazolium salts for HIV-1 infection. The compounds were synthesized via click chemistry with Cu(I) and Ru(II) catalysts. Triazolium salts were synthesized by reaction with methyl iodide or methyl triflate in good yields. The antiviral activity of the compounds was tested using two methodologies: In method one the activity was measured on infected cells; in method two a pre-exposure prophylaxis experimental model was employed. For method one the activity of the compounds was moderate, and in general the triazolium salts showed a decreased activity in relation to their triazole precursors. With method two the antiviral activity was higher. All compounds were able to decrease the infection, with two compounds able to clear almost all the infection, while a lower antiviral activity was noted for the triazolium salts. These results suggest that these drugs could play an important role in the development of pre-exposure prophylaxis therapies.

Indexed as

Drug DevelopmentAnti-HIV AgentsHIV-1Microbial Sensitivity TestsMolecular StructureSaltsTriazolesZidovudineAnti-HIV AgentsSaltsTriazolesZidovudineanti-viralAZTclick chemistryHIV-1triazolestriazolium salts

Identifiers

PMID34771129
PMCPMC8588071
OpenAlexW3214676202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.